CA-ARIBIO
5.1.2023 13:10:39 CET | Business Wire | Press release
AriBio USA, a clinical-stage biopharmaceutical company, announced the enrollment of their first participants in their Phase 3 trial to evaluate the efficacy of AR1001 in participants with early Alzheimer’s Disease (AD). AR1001 is a blood-brain barrier penetrating small molecule known to inhibit neuron apoptosis and promote neurogenesis, increase neuroplasticity and increase autophagy activity to remove toxic proteins.
This study is a randomized, placebo-controlled, double-blind, multi-center Phase 3 trial that plans to enroll 800 participants from approximately 75 sites for 12 months of treatment, followed by an optional two-year extension phase. Patients will be randomly assigned to receive either 30 mg of AR1001 or placebo once daily for 52 weeks. In the optional-extension study, participants originally assigned to placebo will receive 30 mg of AR1001 for an additional two years of treatment. The primary endpoint in the trial is the Change in the Clinical Dementia Rating Scale – Sum of Boxes (CDR-SB) at Week 52. “As we learn more about Alzheimer’s disease with the understanding that different therapeutic approaches are necessary to demonstrate a meaningful benefit to patients and their caregivers we look forward to data on AR1001,” said Dr. Greeley, CMO for AriBio USA.
“AriBio USA is excited to share this significant milestone, and we look forward to providing regular updates to the program as enrollment progresses in this Phase 3 trial. We continue to engage with interested investigators and sites who are committed to making a difference in the treatment and care of patients with Alzheimer’s disease,” said James Rock, CEO of AriBio USA, Inc. Enrollment is expected to require approximately 2 years for this Phase 3 trial. Dr. Greeley stated, “As we understand more about Alzheimer’s disease, with the understanding that different therapeutics and lifestyle approaches will be necessary to demonstrate a meaningful benefit to patients and their caregivers, we expect AR1001 to be part of this treatment paradigm.”
AriBio Ltd, the parent company of AriBio USA, is committed to developing new therapeutics in the neurology space with a pipeline of PDE-5 inhibitors and other new molecular entities. “Our goal is to transform the treatment options available for patients with dementia to improve their daily lives,” stated Dr. Matthew Choung, CEO of AriBio Ltd.
About AR1001-ADP3-US01
AR1001-ADP3-US01 (NCT05531526) is Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease. The study aims to assess the efficacy and safety of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on the development of therapies for neurodegenerative diseases. AriBio USA, INC. is the subsidiary company of AriBio Co., Ltd. based in San Diego, CA in charge of clinical operations and regulatory affairs for AriBio.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005102/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ZAPI GROUP to Showcase New Electrification Solutions at ConExpo/AGG 20263.3.2026 15:03:00 CET | Press release
Electrification leader demonstrates expanded low & high voltage capabilities at North America’s largest construction show ZAPI GROUP, a global leader in electrification, will demonstrate new solution capabilities within industrial vehicle electrification at ConExpo/AGG, taking place (March 3-7) in Las Vegas. As electrified construction equipment evolves to include larger, more demanding applications, the group has developed new higher-powered on-board DC/DC converters, inverters, electrical motors, and battery chargers to support those performance requirements, while combining additional utility functions within a compact form-factor. Featured solutions include: For motive power applications, a third-generation high-voltage inverter (ACH3) with customizable control software for enhanced performance, and a permanent magnet, electrical motor solution (IMI), with an integrated, liquid-cooled power-electronic inverter. On the battery-charging front, there will be new high-voltage, high-pow
Carta Launches CRM with Acquisition of ListAlpha3.3.2026 15:01:00 CET | Press release
Acquisition expands Carta’s AI-first ERP for private capital, creating an institutional-grade platform for deal teams and fundraising professionals to increase capital velocity Carta, the world’s first fully interconnected system for private capital, today announced it has acquired ListAlpha, the AI-powered CRM and relationship intelligence platform. The acquisition marks the launch of Carta CRM, a major expansion of the Carta ERP that further unifies front-to-back office workflows for the private markets. Private equity and venture capital firms have long operated in a fragmented way, keeping relationship context in siloed CRMs while fund performance data remains trapped in back-office ledgers. This information silo quietly erodes clarity for deal teams and GPs, slowing down teams and decreasing capital velocity. By integrating ListAlpha’s specialized CRM directly into the Carta ecosystem, firms can unify front-office intelligence with back-office execution on a single platform. Effec
Flexitech Chooses Rimini Street to Extend the Life of its SAP ECC, Accelerate Compliance and Fund Innovation3.3.2026 15:00:00 CET | Press release
Rimini Support™ for SAP helps French brake parts manufacturer avoid unwanted move to RISE with SAP, strengthen security and compliance readiness and reinvest freed capital into R&D and modernization initiatives Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Flexitech, a French manufacturer of brake and cooling hose solutions for the global automotive industry, has selected Rimini Support™ for SAP to strengthen security, accelerate compliance readiness and free budget for innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303263951/en/ Flexitech Chooses Rimini Street to Extend the Life of its SAP ECC, Accelerate Compliance and Fund Innovation Rimini Support™ Enables Stability, Compliance and Strategic Reinvestment Flexitech relies on a stable SAP ECC 6 environment to support its w
Connect44 Selects Sitetracker to Power Efficient, Scalable Fiber and Wireless Rollouts3.3.2026 15:00:00 CET | Press release
Sitetracker, the global leader in complete Asset Lifecycle Management for critical infrastructure, today announced that Connect44 has selected Sitetracker to support the delivery of its fiber and wireless network projects across Germany, UK and the PMO organisation. By consolidating project execution, field data capture, and reporting on a single platform, Connect44 aims to accelerate delivery speed, reduce operational risk, and strengthen financial performance as it scales its rollout and managed services business. Connect44 provides managed services, professional services, and resource consulting for telecom operators, supporting networks from planning and design through deployment, operations, and optimization. As the company expands into large-scale rollout programs and acts as a general contractor coordinating multiple subcontractors, it identified the need for a centralized platform to replace spreadsheets and operator-specific tools. Sitetracker will serve as Connect44’s system
Wolters Kluwer New Global ‘Future Ready CFO Report’ Finds CFOs Have Stepped Into the Role of Orchestrator3.3.2026 15:00:00 CET | Press release
New research shows CFOs owning digital transformation at 53%, capital allocation at 42%, and risk management at 40%, signaling a shift toward the CFO as enterprise performance orchestrator A new global survey from Wolters Kluwer Corporate Performance and ESG (CP & ESG) reveals that the office of the CFO has moved beyond digital transformation readiness and into an operating reality defined by technology, risk, and strategic accountability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303740372/en/ The findings highlight CFOs as cross‑functional orchestrators, coordinating strategy, risk, and technology across the C‑suite to deliver measurable business impact. In addition to traditional finance leadership tasks, the following data points to a fundamental expansion of the CFO role: 53% of respondents say CFOs own digital transformation, 42% are responsible for capital allocation, and 40% oversee risk management. Maria Mon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom